Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer
Florian Castet(Institut d'Investigació Biomédica de Bellvitge), Teresa Macarulla(Vall d'Hebron Hospital Universitari), Ka Man Mak(Cancer Research UK), Adelaida La Casta(Institut Català d'Oncologia), Marcos Melián, Andre Lopes(Cancer Research UK), Min-Su Kang(Seoul National University Bundang Hospital), Andrés J. Muñoz Martín(Hospital General Universitario Gregorio Marañón), M. Guillot, R. Molina, David Páez, Mercedes Rodríguez-Garrote, Jorge Adeva(Hospital Universitario 12 De Octubre), D. López-Valbuena, Tian V. Tian(Breast Cancer Research Foundation), Jaewon Hyung(Ulsan College), Lorenza Rimassa(Humanitas University), Oscar Alfredo Castillo Trujillo(Hospital Universitario Central de Asturias), Ignacio García Escobar, Javier Sastre(Hospital Clínico San Carlos), Javier Gallego, Ismael Ghanem, John Bridgewater(University College London Hospitals NHS Foundation Trust), Ángela Lamarca(Hospital Universitario Fundación Jiménez Díaz), Carles Fabregat-Franco(Vall d'Hebron Institut de Recerca), Míriam Basagaña-Farrés(Vall d'Hebron Hospital Universitari), Jin Won Kim(Seoul National University Bundang Hospital), Alfredo Castillo(Ulsan College), David Gutiérrez, Ana Fernandez-Montes, Rosario Vidal-Tocino, Simran Vaja(Cancer Research UK), Roberto Pazo-Cid, Enrique Aranda, Inmaculada Alés, Adelaida Lacasta(Vita-Salute San Raffaele University), Inmaculada Gallego, Teresa García García, Ruth Vera, Begoña Graña, Eva Martínez de Castro, Míriam Lobo, Paloma Peinado, Inma Ruiz de Mena, Francesca Salani(Scuola Superiore Sant'Anna), Berta Laquente, Margherita Rimini(Vita-Salute San Raffaele University)
Cited by 4
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
|Nature|2021|1.3k